Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is a multi center, Phase I, Phase II and surgical study of the CX-4945 drug
(silmitasertib sodium) for patients with recurrent SHH (Sonic Hedgehog) medulloblastoma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Pediatric Brain Tumor Consortium
Collaborators:
National Cancer Institute (NCI) St. Jude Children's Research Hospital